Saturday 17 October 2026
Export SGHT’s income statement to Excel — free account
Sight Sciences, Inc.
SGHT Healthcare Medical Devices
Sight Sciences, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $77.4 million, down 3.13% from fiscal 2024. In the quarter to June 2026, revenue grew 19.6%, EPS grew 65.2%, free cash flow grew 26.7% and total debt rose 2.40%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
8.28
0.52
−5.91%
Follow SGHT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
P/E ratio |
+8 more quarters Free account |
0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
2.37 | 5.35 | 2.56 | 3.54 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(20.67) | (226.35) | (28.93) | (52.17) | |
P/B ratio |
2.80 | 6.47 | 3.77 | 5.59 | |
Price to Tangible BV |
2.80 | 6.47 | 3.77 | 5.59 | |
EV/Sales |
1.71 | 4.71 | 2.00 | 3.08 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(4.15) | (12.26) | (6.33) | (11.04) | |
EV/FCF |
(4.08) | (12.11) | (6.26) | (10.99) | |
Quick Ratio |
8.63 | 9.22 | 5.26 | 4.45 | |
Current Ratio |
9.60 | 10.22 | 5.86 | 4.95 | |
Net Debt/EBITDA |
6.93 | 15.52 | 3.68 | 10.98 | |
Debt/Assets |
34.47% | 34.95% | 36.95% | 38.88% | |
Debt/Equity |
0.62 | 0.63 | 0.75 | 0.77 | |
Asset Turnover |
0.59 | 0.60 | 0.66 | 0.74 | |
Operating CF/Net income |
1.07 | 0.44 | 0.54 | 1.27 | |
Capex/Depreciation |
(0.48) | 0.46 | (0.18) | (0.06) | |
Interest Coverage |
(6.05) | (2.85) | (9.79) | (3.01) | |
Research and Development Expense of Revenue |
16.84% | 11.95% | 12.93% | 10.74% | |
Selling, General and Administrative Expense of Revenue |
109.26% | 93.30% | 136.28% | 97.27% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
12.16% | 12.50% | 14.48% | 12.67% | |
Graham Net Nets |
0.34 | 0.15 | 0.25 | 0.17 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(26.16%) | (9.46%) | (18.83%) | (10.33%) | |
Free Cash Flow Yield |
(17.70%) | (7.27%) | (12.49%) | (7.90%) | |
Revenue per Share |
0.38 | 0.39 | 0.37 | 0.43 | |
Operating CF per Share |
(0.17) | (0.03) | (0.13) | (0.10) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.17) | (0.03) | (0.13) | (0.10) | |
Cash per Share |
1.76 | 1.76 | 1.58 | 1.46 | |
Shareholders Equity per Share |
1.23 | 1.23 | 1.00 | 0.97 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
1.23 | 1.23 | 1.00 | 0.97 | |
Free Cash Flow |
(8.89) | (1.67) | (7.09) | (5.68) | |
Working Capital |
101.76 | 101.71 | 88.35 | 80.94 | |
Capital Expenditures |
(0.17) | 0.16 | (0.06) | (0.02) | |
Net Current Asset Value |
61.63 | 61.38 | 50.71 | 49.46 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.01 | (0.01) | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
11.34 | 10.27 | 10.01 | 10.50 | |
Average Payables |
1.52 | 1.52 | 2.13 | 1.99 | |
Average Inventory |
7.04 | 7.05 | 6.41 | 5.95 | |
Average Assets |
129.93 | 129.07 | 119.69 | 113.42 | |
Average Common Equity |
79.62 | 75.73 | 65.77 | 61.45 |
Columns are period end dates